Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael R. Burkhard"'
Autor:
James G. Christensen, Macedonia J. Mejia, Tony Pisal Tang, Joshua Ballard, Pavel Y. Savechenkov, Mark Joseph Chicarelli, Guy Vigers, Niranjan Sudhakar, James F. Blake, Peter D. Olson, Brian R. Baer, David Briere, Matthew A. Marx, Fell Jay Bradford, Michael R. Burkhard, Karyn Bouhana, Laurence E. Burgess, Jill Hallin, Harrah Chiang, John P. Fischer
Publikováno v:
Molecular Cancer Research. 18:B30-B30
The ability to effectively target mutated KRAS has remained elusive despite decades of research. By solving a highly informative set of ligand-complexed co-crystal structures coupled with iterative structure-based drug design, substituted tetrahydrop
Autor:
David Briere, Lauren Hargis, James G. Christensen, Matthew A. Marx, Jill Hallin, Fell Jay Bradford, Lars D. Engstrom, Niranjan Sudhakar, Peter D. Olson, Andrew Calinisan, Michael R. Burkhard, John P. Fischer, Harrah Chiang, Ruth Aranda, Brian R. Baer
Publikováno v:
Molecular Cancer Research. 18:B23-B23
KRAS G12C is a driver mutation and the most frequent KRAS mutation in lung cancer. The ability to effectively target mutated KRAS has remained elusive despite decades of research. A structure-based drug design discovery program identified mutant-sele
Autor:
Peter Olson, David Briere, Matthew A. Marx, Andrew Calinisan, Michael R. Burkhard, Niranjan Sudhakar, Jill Hallin, Lauren Hargis, Fell Jay Bradford, Guy Vigers, Ruth Aranda, Lars D. Engstrom, John P. Fischer, James G. Christensen, James F. Blake, Brian R. Baer, Josh Ballard, Vickie Bowcut
Publikováno v:
Molecular Cancer Therapeutics. 18:C069-C069
The ability to effectively target mutated KRAS has remained elusive despite decades of research. MRTX849 was identified via structure-based drug design as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properti
Autor:
Ruth Aranda, Guy Vigers, James G. Christensen, John Fischer, Andrew Calinisan, Michael R. Burkhard, Lars D. Engstrom, Lauren Hargis, Fell Jay Bradford, David Briere, Matthew A. Marx, Peter D. Olson, Brian R. Baer, James F. Blake, Jill Hallin
Publikováno v:
Cancer Research. 79:LB-271
The ability to effectively target mutated KRAS has remained elusive despite decades of research. By solving a series of co-crystal structures coupled with iterative structure-based drug design, substituted tetrahydropyridopyrimidines were identified